Microscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation☆

被引:0
作者
Verrijssen, A. E. [1 ,2 ]
Van Limbergen, E. J. [1 ]
Bellezzo, M. [1 ]
Grabsch, H. I. [3 ]
Houben, R. [1 ]
Goudkade, D. [4 ]
Melenhorst, J. [5 ]
Samarska, I. [3 ]
Fonseca, G. Paiva [1 ]
Verhaegen, F. [1 ]
Berbee, M. [1 ]
机构
[1] Univ Maastricht, GROW Sch Oncol & Reprod, MAASTRO, Maastricht, Netherlands
[2] Catharina Hosp, Dept Radiotherapy, Eindhoven, Netherlands
[3] Univ Maastricht, Maastricht Univ Med Ctr, GROW Sch Oncol & Reprod, Dept Pathol, Maastricht, Netherlands
[4] Zuyderland Med Ctr, Dept Pathol, Heerlen, Netherlands
[5] Univ Maastricht, Maastricht Univ Med Ctr, GROW Sch Oncol & Reprod, Dept Surg, Maastricht, Netherlands
关键词
Contact brachytherapy; Papillon; Endorectal brachytherapy; Rectal boost; Microscopic intramural spread; Lateral spread; X-RAY BRACHYTHERAPY; QUALITY-OF-LIFE; TUMOR-REGRESSION; CHEMORADIOTHERAPY; RADIOTHERAPY; THERAPY; PRESERVATION; RESECTION; SURVIVAL; ANTERIOR;
D O I
10.1016/j.ctro.2025.100963
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study investigates microscopic intramural spread (MIS) after neoadjuvant (chemo)radiotherapy on Total Mesorectal Excision (TME) specimens of rectal cancer patients and explores the necessity of an additional treatment margin for endorectal radiation boosts (for example through contact brachytherapy (CXB)) or local excisions. Methods: A cohort of patients from Maastricht University Medical Center (MUMC + ) treated between 2016 and 2022 was analyzed. Patients underwent MRI, CT scans, and sigmoidoscopy six weeks after radiotherapy, followed by surgery. Pathological analysis of TME specimens, including whole mount macro-cassettes, was performed to measure residual macroscopic tumor and MIS. Fragmented and continuous MIS were recorded parallel and perpendicular to the bowel wall. Results: Out of 54 patients, 37 (69%) exhibited no MIS. MIS was observed in 4/18 (22%) of patients with ycT1-2 tumors and 13/36 (36%) of patients with ycT3-4 tumors. 4 patients (7%) showed continuous MIS and 15 (28%) showed fragmented MIS. No patients with ypT1-2 had MIS. Conclusions: 69% of patients do not retain MIS post-neoadjuvant therapy. Knowledge of tumor thickness seems crucial for patient selection for CXB.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer
    Chen, Junbing
    Wu, Zhouqiao
    Zhang, Xiaoyan
    Liu, Zining
    Wang, Yiding
    Shan, Fei
    Wang, Yinkui
    Xia, Shaojun
    Zhang, Yan
    Sun, Yingshi
    Ji, Jiafu
    Li, Ziyu
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (11) : 2321 - 2333
  • [22] Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection A pooled analysis of 3,313 patients
    Maas, Monique
    Nelemans, Patty J.
    Valentini, Vincenzo
    Crane, Christopher H.
    Capirci, Carlo
    Roedel, Claus
    Nash, Garrett M.
    Kuo, Li-Jen
    Glynne-Jones, Rob
    Garcia-Aguilar, Julio
    Suarez, Javier
    Calvo, Felipe A.
    Pucciarelli, Salvatore
    Biondo, Sebastiano
    Theodoropoulos, George
    Lambregts, Doenja M. J.
    Beets-Tan, Regina G. H.
    Beets, Geerard L.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (01) : 212 - 220
  • [23] The Influence of Neoadjuvant Chemoradiation for Middle and Lower Rectal Cancer on Anorectal Function
    Hirata, Yugo
    Nozawa, Hiroaki
    Kawai, Kazushige
    Hata, Keisuke
    Tanaka, Toshiaki
    Nishikawa, Takeshi
    Sasaki, Kazuhito
    Kaneko, Manabu
    Emoto, Shigenobu
    Murono, Koji
    Sonoda, Hirofumi
    Ishihara, Soichiro
    ANTICANCER RESEARCH, 2020, 40 (04) : 2199 - 2208
  • [24] Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
    Suwanthanma, Weerapat
    Kitudomrat, Saowanee
    Euanorasetr, Chakrapan
    MEDICINE, 2021, 100 (38)
  • [25] Transanal Local Excision of Rectal Cancer after Neoadjuvant Chemoradiation: Is There a Place for It or Should Be Avoided at All Costs?
    Perez, Rodrigo Oliva
    Pagin Sao Juliao, Guilherme
    Vailati, Bruna Borba
    CLINICS IN COLON AND RECTAL SURGERY, 2022, 35 (02) : 122 - 128
  • [26] Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer
    Lee, Soo Young
    Kim, Chang Hyun
    Kim, Young Jin
    Kim, Hyeong Rok
    ONCOLOGY, 2015, 89 (06) : 311 - 318
  • [27] Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center
    Chen, Nan
    Li, Chang-Long
    Wang, Lin
    Yao, Yun-Feng
    Peng, Yi-Fan
    Zhan, Tian-Cheng
    Zhao, Jun
    Wu, Ai-Wen
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (12)
  • [28] MR prediction of pathologic complete response and early-stage rectal cancer after neoadjuvant chemoradiation in patients with clinical T1/T2 rectal cancer for organ saving strategy
    Bae, Heejin
    Seo, Nieun
    Han, Kyunghwa
    Koom, Woong Sub
    Kim, Myeong-Jin
    Kim, Nam Kyu
    Lim, Joon Seok
    MEDICINE, 2020, 99 (42)
  • [29] Regional lymph node status after neoadjuvant chemoradiation of rectal cancer producing a complete or near complete rectal wall response
    Shwaartz, C.
    Haim, N.
    Rosin, D.
    Lawrence, Y.
    Gutman, M.
    Zmora, O.
    COLORECTAL DISEASE, 2015, 17 (07) : 595 - 599
  • [30] CEA - A Predictor for Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer
    Wallin, Ulrik
    Rothenberger, David
    Lowry, Ann
    Luepker, Russell
    Mellgren, Anders
    DISEASES OF THE COLON & RECTUM, 2013, 56 (07) : 859 - 868